Between 2013 and 2017, RenRX and its principals paid physicians to order pharmacogenetic tests in return for their participation in a clinical trial called the Diagnosing Adverse Drug Reactions Registry, the DOJ alleges. Under the settlement, UTC Laboratories, doing business as RenRX, agreed to pay $41.6 million to resolve allegations that the lab violated the False Claims Act by paying physicians kickbacks for referrals for pharmacogenetic testing, as well as billing for medically unnecessary tests.
The lab’s three principals — Tarun Jolly, MD, Patrick Ridgeway and Barry Griffith — all agreed to pay an additional $1 million to resolve the claims.
RenRX will lose its federal billing privileges for 25 years under the settlement.
More articles on legal and regulatory issues:
Sutter Health antitrust trial delayed
Federal court sends former Tenet physicians’ retaliation claims to arbitration
10 latest healthcare industry lawsuits, settlements
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.